Clinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02498613 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 31, 2016
- Completion date
- April 10, 2027
- Enrollment
- 122 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid neoplasm, metastatic lung non-small cell carcinoma, metastatic lung small cell carcinoma, metastatic pancreatic adenocarcinoma, metastatic triple-negative breast carcinoma, pancreatic ductal adenocarcinoma, stage iii breast cancer ajcc v7, stage iii lung non-small cell cancer ajcc v7, stage iii lung small cell carcinoma ajcc v7, stage iii pancreatic cancer ajcc v6 and v7, stage iiia breast cancer ajcc v7, stage iiia lung non-small cell cancer ajcc v7, stage iiia lung small cell carcinoma ajcc v7, stage iiib breast cancer ajcc v7, stage iiib lung non-small cell cancer ajcc v7, stage iiib lung small cell carcinoma ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, stage iv lung non-small cell cancer ajcc v7, stage iv lung small cell carcinoma ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, triple-negative breast carcinoma, unresectable lung small cell carcinoma, unresectable pancreatic adenocarcinoma, unresectable pancreatic carcinoma, unresectable triple-negative breast carcinoma